{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T06:25:07Z","timestamp":1793082307060,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,12,5]],"date-time":"2018-12-05T00:00:00Z","timestamp":1543968000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2018,12,5]],"date-time":"2018-12-05T00:00:00Z","timestamp":1543968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s40123-018-0156-4","type":"journal-article","created":{"date-parts":[[2018,12,5]],"date-time":"2018-12-05T16:15:01Z","timestamp":1544026501000},"page":"125-136","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["The Ocular Status of Cystinosis Patients Receiving a Hospital Pharmacy-Made Preparation of Cysteamine Eye Drops: A Case Series"],"prefix":"10.1007","volume":"8","author":[{"given":"Susmito","family":"Biswas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishanthy","family":"Sornalingam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,12,5]]},"reference":[{"key":"156_CR1","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1126\/science.7112129","volume":"217","author":"WA Gahl","year":"1982","unstructured":"Gahl WA, Bashan N, Tietze F, Bernardini I, Schulman JD. Cystine transport is defective in isolated leukocyte lysosomes from patients with cystinosis. Science. 1982;217:1263\u20135.","journal-title":"Science"},{"key":"156_CR2","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMra020552","volume":"347","author":"WA Gahl","year":"2002","unstructured":"Gahl WA, Thoene JG, Schneider JA. Cystinosis. N Engl J Med. 2002;347:111\u201321.","journal-title":"N Engl J Med"},{"key":"156_CR3","doi-asserted-by":"publisher","first-page":"242","DOI":"10.7326\/0003-4819-147-4-200708210-00006","volume":"147","author":"WA Gahl","year":"2007","unstructured":"Gahl WA, Balog JZ, Kleta R. Nephropathic cystinosis in adults: natural history and effects of oral cysteamine therapy. Ann Intern Med. 2007;147:242\u201350.","journal-title":"Ann Intern Med"},{"key":"156_CR4","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00467-003-1077-5","volume":"18","author":"V Kalatzis","year":"2003","unstructured":"Kalatzis V, Antignac C. New aspects of the pathogenesis of cystinosis. Pediatr Nephrol. 2003;18:207\u201315.","journal-title":"Pediatr Nephrol"},{"key":"156_CR5","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/ng0498-319","volume":"18","author":"M Town","year":"1998","unstructured":"Town M, Jean G, Cherqui S, et al. A novel gene encoding an integral membrane protein is mutated in nephropathic cystinosis. Nat Genet. 1998;18:319\u201324.","journal-title":"Nat Genet"},{"key":"156_CR6","doi-asserted-by":"publisher","first-page":"F905","DOI":"10.1152\/ajprenal.00318.2010","volume":"299","author":"MJ Wilmer","year":"2010","unstructured":"Wilmer MJ, Emma F, Levtchenko EN. The pathogenesis of cystinosis: mechanisms beyond cystine accumulation. Am J Physiol Renal Physiol. 2010;299:F905\u201316.","journal-title":"Am J Physiol Renal Physiol"},{"key":"156_CR7","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/978-3-540-76341-3_41","volume-title":"Pediatric nephrology","author":"W Gahl","year":"2009","unstructured":"Gahl W. Cystinosis. In: Avner ED, Harmon WE, Niaudet P, Yoshikawa N, editors. Pediatric nephrology. 6th ed. Berlin Heidelberg: Springer; 2009. p. 1019\u20132038.","edition":"6"},{"key":"156_CR8","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1016\/j.jpeds.2016.12.055","volume":"183S","author":"R Bishop","year":"2017","unstructured":"Bishop R. Ocular complications of infantile nephropathic cystinosis. J Pediatr. 2017;183S:S19\u201321.","journal-title":"J Pediatr"},{"key":"156_CR9","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.2147\/OPTH.S36626","volume":"8","author":"F Shams","year":"2014","unstructured":"Shams F, Livingstone I, Oladiwura D, Ramaesh K. Treatment of corneal cystine crystal accumulation in patients with cystinosis. Clin Ophthalmol. 2014;8:2077\u201384.","journal-title":"Clin Ophthalmol"},{"key":"156_CR10","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1001\/archopht.1986.01050170096030","volume":"104","author":"MI Kaiser-Kupfer","year":"1986","unstructured":"Kaiser-Kupfer MI, Caruso RC, Minkler DS, Gahl WA. Long-term ocular manifestations in nephropathic cystinosis. Arch Ophthalmol. 1986;104:706\u201311.","journal-title":"Arch Ophthalmol"},{"key":"156_CR11","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/00003226-200203000-00009","volume":"21","author":"ET Tsilou","year":"2002","unstructured":"Tsilou ET, Rubin BI, Reed GF, Iwata F, Gahl W, Kaiser-Kupfer MI. Age-related prevalence of anterior segment complications in patients with infantile nephropathic cystinosis. Cornea. 2002;21:173\u20136.","journal-title":"Cornea"},{"key":"156_CR12","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1097\/MOP.0000000000000462","volume":"29","author":"KR Veys","year":"2017","unstructured":"Veys KR, Elmonem MA, Arcolino FO, van den Heuvel L, Levtchenko E. Nephropathic cystinosis: an update. Curr Opin Pediatr. 2017;29:168\u201378.","journal-title":"Curr Opin Pediatr"},{"key":"156_CR13","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1056\/NEJM198704163161602","volume":"316","author":"WA Gahl","year":"1987","unstructured":"Gahl WA, Reed GF, Thoene JG, et al. Cysteamine therapy for children with nephropathic cystinosis. N Engl J Med. 1987;316:971\u20137.","journal-title":"N Engl J Med"},{"key":"156_CR14","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1056\/NEJM199304223281604","volume":"328","author":"TC Markello","year":"1993","unstructured":"Markello TC, Bernardini IM, Gahl WA. Improved renal function in children with cystinosis treated with cysteamine. N Engl J Med. 1993;328:1157\u201362.","journal-title":"N Engl J Med"},{"issue":"6","key":"156_CR15","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/eye.1991.139","volume":"5","author":"JA Bradbury","year":"1991","unstructured":"Bradbury JA, Danjoux JP, Voller J, Spencer M, Brocklebank T. A randomised placebo-controlled trial of topical cysteamine therapy in patients with nephropathic cystinosis. Eye (Lond). 1991;5(6):755\u201360.","journal-title":"Eye (Lond)"},{"key":"156_CR16","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1006\/mgme.1998.2725","volume":"64","author":"F Iwata","year":"1998","unstructured":"Iwata F, Kuehl EM, Reed GF, McCain LM, Gahl WA, Kaiser-Kupfer MI. A randomized clinical trial of topical cysteamine disulfide (cystamine) versus free thiol (cysteamine) in the treatment of corneal cystine crystals in cystinosis. Mol Genet Metab. 1998;64:237\u201342.","journal-title":"Mol Genet Metab"},{"key":"156_CR17","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1056\/NEJM198703263161304","volume":"316","author":"MI Kaiser-Kupfer","year":"1987","unstructured":"Kaiser-Kupfer MI, Fujikawa L, Kuwabara T, Jain S, Gahl WA. Removal of corneal crystals by topical cysteamine in nephropathic cystinosis. N Engl J Med. 1987;316:775\u20139.","journal-title":"N Engl J Med"},{"key":"156_CR18","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1001\/archopht.1990.01070070075038","volume":"108","author":"MI Kaiser-Kupfer","year":"1990","unstructured":"Kaiser-Kupfer MI, Gazzo MA, Datiles MB, Caruso RC, Kuehl EM, Gahl WA. A randomized placebo-controlled trial of cysteamine eye drops in nephropathic cystinosis. Arch Ophthalmol. 1990;108:689\u201393.","journal-title":"Arch Ophthalmol"},{"key":"156_CR19","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1136\/bjo.87.1.28","volume":"87","author":"ET Tsilou","year":"2003","unstructured":"Tsilou ET, Thompson D, Lindblad AS, et al. A multicentre randomised double masked clinical trial of a new formulation of topical cysteamine for the treatment of corneal cystine crystals in cystinosis. Br J Ophthalmol. 2003;87:28\u201331.","journal-title":"Br J Ophthalmol"},{"key":"156_CR20","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1002\/jppr.1148","volume":"45","author":"B Radojkovic","year":"2015","unstructured":"Radojkovic B. Cysteamine eye drops in the treatment of cystinosis\u2014an Australian perspective. J Pharm Pract Res. 2015;45:440\u20135.","journal-title":"J Pharm Pract Res"},{"key":"156_CR21","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1136\/bjophthalmol-2016-309278","volume":"101","author":"A Al-Hemidan","year":"2017","unstructured":"Al-Hemidan A, Shoughy SS, Kozak I, Tabbara KF. Efficacy of topical cysteamine in nephropathic cystinosis. Br J Ophthalmol. 2017;101:1234\u20137.","journal-title":"Br J Ophthalmol"},{"key":"156_CR22","doi-asserted-by":"crossref","first-page":"272","DOI":"10.3928\/0191-3913-19900901-14","volume":"27","author":"IM MacDonald","year":"1990","unstructured":"MacDonald IM, Noel LP, Mintsioulis G, Clarke WN. The effect of topical cysteamine drops on reducing crystal formation within the cornea of patients affected by nephropathic cystinosis. J Pediatr Ophthalmol Strabismus. 1990;27:272\u20134.","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"156_CR23","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s40267-017-0398-6","volume":"33","author":"KA Lyseng-Williamson","year":"2017","unstructured":"Lyseng-Williamson KA. Cystadrops (cysteamine hydrochloride 0.55% viscous eye-drops solution) in treating corneal cystine crystal deposits in patients with cystinosis: a profile of its use. Drugs Ther Perspect. 2017;33:195\u2013201.","journal-title":"Drugs Ther Perspect"},{"key":"156_CR24","doi-asserted-by":"crossref","unstructured":"Reda A, Van Schepdael A, Adams E, et al. Effect of storage conditions on stability of ophthalmological compounded cysteamine eye drops. JIMD Rep. 2018;42:47\u201351.","DOI":"10.1007\/8904_2017_77"},{"issue":"2","key":"156_CR25","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s40123-018-0146-6","volume":"7","author":"S Biswas","year":"2018","unstructured":"Biswas S, Gaviria M, Malheiro L, Marques JP, Giordano V, Liang H. Latest clinical approaches in the ocular management of cystinosis: a review of current practice and opinion from the ophthalmology cystinosis forum. Ophthalmol Ther. 2018;7(2):307\u2013322.","journal-title":"Ophthalmol Ther"},{"key":"156_CR26","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1006\/mgme.2000.3062","volume":"71","author":"WA Gahl","year":"2000","unstructured":"Gahl WA, Kuehl EM, Iwata F, Lindblad A, Kaiser-Kupfer MI. Corneal crystals in nephropathic cystinosis: natural history and treatment with cysteamine eyedrops. Mol Genet Metab. 2000;71:100\u201320.","journal-title":"Mol Genet Metab"},{"key":"156_CR27","doi-asserted-by":"publisher","first-page":"3218","DOI":"10.1167\/iovs.15-16499","volume":"56","author":"H Liang","year":"2015","unstructured":"Liang H, Baudouin C, Hassani RTJ, Brignole-Baudouin F, Labbe A. Photophobia and corneal crystal density in nephropathic cystinosis: an in vivo confocal microscopy and anterior-segment optical coherence tomography study. Invest Ophthalmol Vis Sci. 2015;56:3218\u201325.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"156_CR28","doi-asserted-by":"publisher","first-page":"142","DOI":"10.3928\/0191-3913-20030501-07","volume":"40","author":"P Dureau","year":"2003","unstructured":"Dureau P, Broyer M, Dufier JL. Evolution of ocular manifestations in nephropathic cystinosis: a long-term study of a population treated with cysteamine. J Pediatr Ophthalmol Strabismus. 2003;40:142\u20136.","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"156_CR29","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3109\/13816818709028529","volume":"8","author":"JL Dufier","year":"1987","unstructured":"Dufier JL, Dhermy P, Gubler MC, Gagnadoux MF, Broyer M. Ocular changes in long-term evolution of infantile cystinosis. Ophthalmic Paediatr Genet. 1987;8:131\u20137.","journal-title":"Ophthalmic Paediatr Genet"},{"key":"156_CR30","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s40123-017-0089-3","volume":"6","author":"AM Pinxten","year":"2017","unstructured":"Pinxten AM, Hua MT, Simpson J, Hohenfellner K, Levtchenko E, Casteels I. Clinical Practice: a proposed standardized ophthalmological assessment for patients with cystinosis. Ophthalmol Ther. 2017;6:93\u2013104.","journal-title":"Ophthalmol Ther"},{"key":"156_CR31","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.survophthal.2006.10.006","volume":"52","author":"E Tsilou","year":"2007","unstructured":"Tsilou E, Zhou M, Gahl W, Sieving PC, Chan CC. Ophthalmic manifestations and histopathology of infantile nephropathic cystinosis: report of a case and review of the literature. Surv Ophthalmol. 2007;52:97\u2013105.","journal-title":"Surv Ophthalmol"},{"key":"156_CR32","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1136\/bjo.75.5.311","volume":"75","author":"NP Jones","year":"1991","unstructured":"Jones NP, Postlethwaite RJ, Noble JL. Clearance of corneal crystals in nephropathic cystinosis by topical cysteamine 0.5%. Br J Ophthalmol. 1991;75:311\u20132.","journal-title":"Br J Ophthalmol"},{"issue":"1\u20132","key":"156_CR33","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.ijpharm.2016.10.044","volume":"515","author":"B McKenzie","year":"2016","unstructured":"McKenzie B, Kay G, Matthews KH, Knott R, Cairns D. Preformulation of cysteamine gels for treatment of the ophthalmic complications in cystinosis. Int J Pharm. 2016;515(1\u20132):575\u201382.","journal-title":"Int J Pharm"},{"key":"156_CR34","unstructured":"European Medicines Agency: Cystadrops 3.8\u00a0mg\/mL eye drops solution. Summary of product characteristics. http:\/\/www.ema.europa.eu\/documents\/product-information\/cystadrops-epar-product-information_en.pdf (2017). Accessed 3 Oct 2018."},{"key":"156_CR35","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.ymgme.2013.12.298","volume":"111","author":"A Labbe","year":"2014","unstructured":"Labbe A, Baudouin C, Deschenes G, et al. A new gel formulation of topical cysteamine for the treatment of corneal cystine crystals in cystinosis: the Cystadrops OCT-1 study. Mol Genet Metab. 2014;111:314\u201320.","journal-title":"Mol Genet Metab"},{"key":"156_CR36","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1167\/iovs.16-21080","volume":"58","author":"H Liang","year":"2017","unstructured":"Liang H, Labbe A, Le Mouhaer J, Plisson C, Baudouin C. A new viscous cysteamine eye drops treatment for ophthalmic cystinosis: an open-label randomized comparative phase III pivotal study. Invest Ophthalmol Vis Sci. 2017;58:2275\u201383.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"156_CR37","unstructured":"Royal College of Ophthalmologists, UK Ophthalmic Pharmacy Group: Ophthalmic special order products. http:\/\/www.rcophth.ac.uk\/wp-content\/uploads\/2016\/09\/Ophthalmic-Special-Order-Products-updated-August-2016.pdf (2016). Accessed 2018."},{"issue":"2","key":"156_CR38","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.ijpharm.2017.11.059","volume":"544","author":"P Dixon","year":"2018","unstructured":"Dixon P, Fentzke RC, Bhattacharya A, Konar A, Hazra S, Chauhan A. In vitro drug release and in vivo safety of vitamin E and cysteamine loaded contact lenses. Int J Pharm. 2018;544(2):380\u201391.","journal-title":"Int J Pharm"},{"key":"156_CR39","doi-asserted-by":"publisher","first-page":"3468","DOI":"10.1021\/acs.molpharmaceut.6b00488","volume":"13","author":"DC Marcano","year":"2016","unstructured":"Marcano DC, Shin CS, Lee B, et al. Synergistic cysteamine delivery nanowafer as an efficacious treatment modality for corneal cystinosis. Mol Pharm. 2016;13:3468\u201377.","journal-title":"Mol Pharm"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-018-0156-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-018-0156-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-018-0156-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T11:53:06Z","timestamp":1724413986000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-018-0156-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,5]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["156"],"URL":"https:\/\/doi.org\/10.1007\/s40123-018-0156-4","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,5]]},"assertion":[{"value":"8 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2018","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}